A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma
Clinical trial NCT04981899 · UNKNOWN
Trial details
- NCT number
- NCT04981899
- Sponsor
- St. Petersburg State Pavlov Medical University
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-01
- Primary completion
- 2023-10-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.